treatment-emergent adverse event


Also found in: Acronyms.

treatment-emergent adverse event

An event that first appears during treatment, which was absent before or which worsens relative to the pre-treatment state.
References in periodicals archive ?
The overall incidence of treatment-emergent adverse events (TEAEs) was similar in patients receiving zonisamide compared to placebo.
9% of the treatment and placebo groups, respectively, experienced treatment-emergent adverse events, most were mild or moderate.
The total number of treatment-emergent adverse events was not significantly different between the OSP and placebo groups (290 vs.
The most frequently reported treatment-emergent adverse events in the trial were hypokalemia, anemia, and postoperative ileus.
The incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) were comparable between all finerenone treatment groups and standard therapy.
The results of the study showed a low incidence of serious treatment-emergent adverse events (TEAEs) (2.
The percentage of patients with treatment-emergent adverse events that were determined by the investigators to be related to the study drug was lowest in the TAK-875 patients (7%, compared with 11% in the placebo group and 23% in the glimepiride group).
the overall number of treatment-emergent adverse events, changes in laboratory
The most common non-hematologic treatment-emergent adverse events in all patients in the PACE trial included rash (38%), abdominal pain (38%), headache (35%), dry skin (35%), and constipation (34%), with the majority of these being grades 1 or 2 in severity.
The most frequently reported treatment-emergent adverse events were gastrointestinal disorders, which were reported by eight sotagliflozin patients (50%) compared with three placebo patients (18%), with the most notable imbalance being three reports of nausea on sotagliflozin versus one on placebo.